Effect | Decrease |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 30 |
Sex | Both Genders |
Age Range | 45-64, 65+ |
Body Types | Average |
Subjects between 50 and 80 that suffered from non-clinical cognitive impairment has improvement as measured by the 'Revised Hasegawa Dementia Scale' with 3g of 96% Yamabushitake daily for 16 weeks.